Search Results - "Fashoyin, Ibilola"

FDA Approval Summary: Ramucirumab for Gastric Cancer by Casak, Sandra J, Fashoyin-Aje, Ibilola, Lemery, Steven J, Zhang, Lillian, Jin, Runyan, Li, Hongshan, Zhao, Liang, Zhao, Hong, Zhang, Hui, Chen, Huanyu, He, Kun, Dougherty, Michele, Novak, Rachel, Kennett, Sarah, Khasar, Sachia, Helms, Whitney, Keegan, Patricia, Pazdur, Richard

“…The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric or gastroesophageal junction…”
Get full text

Antibiotic therapy and association with oncological outcomes from targeted and immune-based therapy in hepatocellular carcinoma (HCC) by Pinato, David J. James, Li, Xiaoxue, Mishra-Kalyani, Pallavi Shruti, D'Alessio, Antonio, Fulgenzi, Claudia A.M., Wei, Guo, Schneider, Julie A., Rivera, Donna, Pazdur, Richard, Theoret, Marc Robert, Casak, Sandra J., Lemery, Steven, Fashoyin, Ibilola, Cortellini, Alessio, Pelosof, Lorraine Cheryl

“…4089 Background: Immune checkpoint inhibitors (ICI) alone or in combination with tyrosine kinase (TKI) or VEGF pathway inhibitors (VEGFi) are therapeutic…”
Get full text

Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition by Daly, Robert Michael, Brawley, Otis W., Gospodarowicz, Mary K., Olopade, Olufunmilayo I., Fashoyin, Ibilola, Wolodzko Smart, Victoria, Chang, I-Fen, Tendler, Craig L., Kim, Geoff, Fuchs, Charles S., Zhang, Lianshan, Legos, Jeffrey J., Duran, Cristina, Kalidas, Chitkala, Qian, Jing, Finnegan, Justin, Pilarski, Piotr, Silverstein, Amy, Wu, Yi-Long, Li, Bob T.

“…1584 Background: Fewer than 5% of patients with cancer enroll in a clinical trial, partly due to the significant financial and logistical burden on patients,…”
Get full text

Positive Predictive Value of Tissue Transglutaminase: A Retrospective Review at Our Institution: 252 by Park, Thomas, Fashoyin, Ibilola, Menegus, Marilyn A., DeCross, Arthur J.

Get full text

Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination by Ntowe, Koumani W., McAdoo, Sallie, Haas, Naomi B., Karam, Jose A., Lara, Primo N., Fashoyin-Aje, Ibilola, Saraiya, Biren P., Maskens, Deborah, Pickering, Lisa, Master, Viraj A., Zhang, Tian, Kaye, Deborah R.

“…Background: Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall…”
Get full text